The cannabidiol (CBD) industry’s rapid growth reflects the many needs this compound meets. However, regulatory and health issues related to its use remain unaddressed. This analysis shines a light on the regulatory landscape and applications related to the global CBD industry.
The analysis’ geographic segmentation reflects the specific realities of North America; Europe, the Middle East, and Africa (EMEA); Asia-Pacific; and Latin America. Further segmentation breaks down CBD as an ingredient in end applications: Food and beverages, personal care and cosmetics, and single servings (capsules, oils, gummies). While several properties and benefits of using CBD are apparent, scientific evidence is lacking to demonstrate them effectively. Prescription CBD-based drugs must receive approval from competent authorities in each jurisdiction. The control and compliance of these medicines require clinical trials, while CBD does not. Therefore, the scope of this analysis does not consider pharmaceutically derived products.
GROWTH PIPELINE DIALOG™
Take your first step towards achieving growth-centric solutions with our
Growth Pipeline Dialog™. Speak to our industry experts in a complimentary open discussion that will spark innovative thinking and growth opportunities that will benefit your organization.
